Skip to main content
OpenTrials
Completed

NCT Number: NCT04883216

Investigation of the Characteristics of Chronic Pain Developing After COVID-19

Data on pain after COVID-19 were generally collected from hospitalized patients and only include information on acute pain conditions. However, the characteristics of the chronic pain experienced after COVID-19 are unknown. For this reason, the treatment and recommendations for patients who present with chronic pain after COVID-19 are not clear. Our goal is to determine the characteristics and risk factors of chronic pain developing in COVID-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Chronic Pain Coronaviridae Infections Coronavirus Coronavirus Infections Infections Lung Diseases Neurologic Manifestations Nidovirales Infections Pain Pathological Conditions, Signs and Symptoms Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istanbul University Istanbul Faculty of Medicine

Istanbul, 34093, Turkey (Türkiye)

About this study

Data on pain developing after COVID-19 were generally collected from hospitalized patients and only include information on acute pain conditions seen after the ilness. It is noteworthy that headache and musculoskeletal pain were seen common in first few weeks. However, the characteristics (mechanical, inflammatory, central sensitization, anxiety-related, etc.) of the chronic pain experienced are unknown. For this reason, the treatment and recommendations for patients who present with chronic pain after COVID-19 are not clear. Our goal is to determine the characteristics and risk factors of chronic pain developing in COVID-19 patients and to create specific treatment recommendations for these patient groups with further studies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Being over the age of 18
  • SARS-CoV-2 infection demonstrated with the PCR test (testing date irrelevant)
  • Pain developed or increased after having COVID-19

Exclusion criteria

  • Mental retardation or mental status not eligible to answer the questionnaires

Treatment and study plan

Primary outcomes

  1. Self-Leeds Assessment of Neuropathic Symptoms & Signs (S-LANSS) Pain Score

    Time frame: up to 1 year

    The S-LANSS aims to identify pain of predominantly neuropathic origin, as distinct from nociceptive pain, without the need for clinical examination.

  2. The Hospital Anxiety and Depression Scale (HADS) Score

    Time frame: up to 1 year

    The Hospital Anxiety and Depression Scale (HADS) is a self-assessment questionnaire that has been found to be a reliable instrument for detecting states of anxiety and depression in the setting of hospital outpatient clinic. The HADS questionnaire has seven items each for depression and anxiety subscales.

  3. Central Sensitization Inventory (CSI)

    Time frame: up to 1 year

    The Central Sensitisation Inventory (CSI) is a self-report outcome measure designed to identify patients who have symptoms that may be related to central sensitisation (CS) or central sensitivity syndromes (CSS) such as fibromyalgia, neck injury, temporomandibular joint disorder or migraine/tension headaches. CSI includes 25 questions related to common CSS symptoms.

  4. Self-report Demographic Questionnaire

    Time frame: up to 1 year

    A questionnaire made by the researchers to understand the demographic characteristics of the patients included.

  5. Visual Analog Scale (VAS) for Pain

    Time frame: up to 1 year

    The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain."

Sponsors and collaborators

Lead sponsor

Istanbul University

Other

Registry information

Official study title

Investigation of the Characteristics of Chronic Pain Developing After COVID-19 in Patients With COVID-19

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
May 12, 2021
Registry last updated
Apr 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.